{"id":"https://openalex.org/W4410816632","doi":"https://doi.org/10.1200/jco.2025.43.16_suppl.e16520","title":"Adjuvant toripalimab in high-risk renal cell carcinoma after tumor resection (TUOAD-RCC): A prospective phase 2 study.","display_name":"Adjuvant toripalimab in high-risk renal cell carcinoma after tumor resection (TUOAD-RCC): A prospective phase 2 study.","publication_year":2025,"publication_date":"2025-05-28","ids":{"openalex":"https://openalex.org/W4410816632","doi":"https://doi.org/10.1200/jco.2025.43.16_suppl.e16520"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2025.43.16_suppl.e16520","doi":"https://doi.org/10.1200/jco.2025.43.16_suppl.e16520","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.e16520","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5036133705","display_name":"Shimiao Zhu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210133270","display_name":"Second Hospital of Tianjin Medical University","ror":"https://ror.org/03rc99w60","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210133270"]},{"id":"https://openalex.org/I5740404","display_name":"Tianjin Medical University","ror":"https://ror.org/02mh8wx89","country_code":"CN","type":"education","lineage":["https://openalex.org/I5740404"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Shimiao Zhu","raw_affiliation_strings":["Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin, China","institution_ids":["https://openalex.org/I4210133270","https://openalex.org/I5740404"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5026689418","display_name":"Changyi Quan","orcid":"https://orcid.org/0000-0002-3511-5604","observed_orcids":["https://orcid.org/0000-0002-3511-5604"]},"institutions":[{"id":"https://openalex.org/I4210133270","display_name":"Second Hospital of Tianjin Medical University","ror":"https://ror.org/03rc99w60","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210133270"]},{"id":"https://openalex.org/I5740404","display_name":"Tianjin Medical University","ror":"https://ror.org/02mh8wx89","country_code":"CN","type":"education","lineage":["https://openalex.org/I5740404"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Changyi Quan","raw_affiliation_strings":["The Second Hospital of Tianjin Meidical University, Tianjin, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Second Hospital of Tianjin Meidical University, Tianjin, China","institution_ids":["https://openalex.org/I4210133270","https://openalex.org/I5740404"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"43","issue":"16_suppl","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.007300000172108412,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11297","display_name":"Ferroptosis and cancer prognosis","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/toripalimab","display_name":"toripalimab","score":0.902999997138977},{"id":"https://openalex.org/keywords/adjuvant-immunotherapy","display_name":"adjuvant immunotherapy","score":0.8309999704360962},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.8500000238418579},{"id":"https://openalex.org/keywords/high-risk-renal-cell-carcinoma","display_name":"high-risk renal cell carcinoma","score":0.8209999799728394},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.6629999876022339},{"id":"https://openalex.org/keywords/nephrectomy","display_name":"nephrectomy","score":0.9409999847412109},{"id":"https://openalex.org/keywords/partial-nephrectomy","display_name":"partial nephrectomy","score":0.9700000286102295},{"id":"https://openalex.org/keywords/disease-free-survival","display_name":"disease-free survival","score":0.9290000200271606},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9580000042915344},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.7940000295639038},{"id":"https://openalex.org/keywords/immune-markers","display_name":"immunological markers","score":0.5600000023841858},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.6970000267028809},{"id":"https://openalex.org/keywords/tumor-infiltrating-macrophages","display_name":"tumor-infiltrating macrophages","score":0.6830000281333923},{"id":"https://openalex.org/keywords/tumor-infiltrating-neutrophils","display_name":"tumor-infiltrating neutrophils","score":0.6660000085830688},{"id":"https://openalex.org/keywords/tumor-infiltrating-t-cells","display_name":"tumor-infiltrating T cells","score":0.5099999904632568}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9228980541229248},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.7953012585639954},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.6062783002853394},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.540864884853363},{"id":"https://openalex.org/C159110652","wikidata":"https://www.wikidata.org/wiki/Q17078201","display_name":"Resection","level":2,"score":0.5294159054756165},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.49173691868782043},{"id":"https://openalex.org/C188816634","wikidata":"https://www.wikidata.org/wiki/Q2113324","display_name":"Prospective cohort study","level":2,"score":0.4204164743423462},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.23698171973228455}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2025.43.16_suppl.e16520","doi":"https://doi.org/10.1200/jco.2025.43.16_suppl.e16520","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.e16520","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8600000143051147}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4251003423","https://openalex.org/W2386116568","https://openalex.org/W2944387023","https://openalex.org/W2378135797","https://openalex.org/W2349441096","https://openalex.org/W2419002337","https://openalex.org/W2892370718","https://openalex.org/W3011494554","https://openalex.org/W2384493525","https://openalex.org/W2387425470"],"abstract_inverted_index":{"e16520":[0],"Background:":[1],"Adjuvant":[2],"pembrolizumab":[3],"therapy":[4,43],"after":[5,171,216,237,250],"surgery":[6,50,187],"for":[7,44,104],"renal-cell":[8],"carcinoma":[9],"(RCC)":[10],"improved":[11],"overall":[12],"survival":[13,17],"(OS)":[14],"and":[15,28,61,118,123,139,151,162,176,229,273,295,351,384,400],"disease-free":[16,230],"(DFS),":[18],"However,":[19],"the":[20,59,209,217,253,339,371,398],"other":[21,316],"immune":[22,136],"checkpoint":[23],"inhibitors":[24],"(ICIs),":[25],"including":[26,80,293],"atezolizumab":[27],"nivolumab\u00b1ipilimumab,":[29],"failed":[30],"to":[31,57,113,149,188,200,306,333,367,378],"have":[32],"effect":[33],"on":[34],"disease":[35,207],"control.":[36],"The":[37,131,183,222,318,352,361],"contradictory":[38],"results":[39],"represent":[40],"effective":[41],"adjuvant":[42,64,94,169,220,308,403],"patients":[45,81,156,211,225,249,291,304,320,337],"with":[46,82],"high-risk":[47,67,84,408],"RCC":[48,68,85,406],"following":[49,69],"still":[51],"unmet":[52],"need.":[53],"This":[54,72],"study":[55],"is":[56],"assess":[58],"efficacy":[60,401],"safety":[62,119,399],"of":[63,99,166,219,224,243,285,311,327,342,355,382,402,409],"toripalimab":[65,95,170,309,323,404],"in":[66,179,208,247,289,299,370,405],"nephrectomy.":[70],"Methods:":[71],"was":[73,147,194,203,374],"an":[74],"open-label":[75],"phase":[76],"2":[77,290],"clinical":[78],"trial":[79,414],"resectable":[83],"who":[86,226,321],"received":[87,168,324],"nephrectomy":[88,91,172,175],"or":[89,173,281,315,411],"partial":[90,174],"followed":[92],"by":[93],"(at":[96],"a":[97,238,325],"dose":[98],"240mg)":[100],"every":[101],"21":[102],"days":[103],"17":[105],"cycles.":[106],"Participants":[107],"were":[108,126,135,141,157,177,234,257],"enrolled":[109,158],"from":[110,143,186,198,331,365,386],"October":[111],"2022":[112,161],"December":[114],"2024.":[115],"DFS,":[116],"OS":[117],"(adverse":[120],"events":[121,284],"[AEs]":[122],"patient-reported":[124],"quality-of-life)":[125],"both":[127,235],"primary":[128],"end":[129,133],"points.":[130],"secondary":[132],"points":[134],"biomarkers.":[137],"RNA":[138,150],"DNA":[140],"isolated":[142],"pretreatment":[144],"tumor":[145],"tissue":[146],"subjected":[148],"next-generation":[152],"sequencings.":[153],"Results:":[154],"Forty-four":[155],"between":[159],"July":[160],"September":[163],"2024,":[164],"38":[165,210],"them":[167],"included":[178],"intention-to-treat":[180],"(ITT)":[181],"analysis.":[182],"median":[184,326],"time":[185],"data-cutoff":[189],"date":[190],"(January":[191],"17,":[192],"2025)":[193],"10.3":[195],"months":[196,215,233],"(range":[197,330],"1.2":[199],"28.7).":[201],"There":[202],"only":[204],"one":[205],"progressed":[206],"occurred":[212,288],"at":[213,231,407],"25.0":[214],"beginning":[218],"toripalimab.":[221],"percentage":[223],"remained":[227],"alive":[228],"24":[232],"100%":[236],"moderate":[239],"follow-up":[240],"time.":[241],"AEs":[242,314],"any":[244,286],"grade":[245,313],"emerged":[246],"30":[248],"receiving":[251],"toripalimab,":[252],"most":[254],"common":[255],"ones":[256],"rash":[258],"(n":[259,264,269,275],"=":[260,265,270,276],"10,":[261],"26.3%),":[262],"hypoadrenocorticism":[263],"8,":[266],"21.1%),":[267],"hyperthyroidism":[268],"7,":[271,277],"18.4%)":[272],"fatigue":[274],"18.4%).":[278],"Grade":[279],"3":[280],"higher":[282],"adverse":[283],"cause":[287],"(5.3%),":[292],"myocardial":[294],"hepatic":[296],"injuries,":[297],"result":[298],"treatment":[300],"discontinuation.":[301],"Additional":[302],"12":[303],"refused":[305],"continue":[307],"because":[310],"low":[312],"reasons.":[317],"14":[319],"discontinued":[322],"7":[328],"cycles":[329],"1":[332],"16)":[334],"treatment.":[335],"All":[336],"completed":[338],"Functional":[340],"Assessment":[341],"Cancer":[343,353],"Therapy":[344],"Kidney":[345],"Symptom":[346],"Index\u2013Disease-Related":[347],"Symptoms":[348],"(FKSI-DRS)":[349],"assessments":[350],"Quality":[354],"Life":[356],"Questionnaire":[357],"(EORTC":[358],"QLQ-C30)":[359],"questionnaires.":[360],"least-squares":[362],"mean":[363],"change":[364],"baseline":[366],"week":[368],"52":[369],"FKSI-DRS":[372],"score":[373,381],"\u22121.75":[375],"(95%CI,":[376],"\u22120.47":[377],"\u22123.02).":[379],"Each":[380],"function":[383],"symptom":[385],"EORTC":[387],"QLQ-C30":[388],"didn\u2019t":[389],"show":[390],"significant":[391],"change.":[392],"Conclusions:":[393],"Our":[394],"data":[395],"preliminarily":[396],"demonstrated":[397],"recurrence":[410],"progression.":[412],"Clinical":[413],"information:":[415],"NCT06584435":[416],".":[417]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2025-10-10T00:00:00"}